Comparative Pharmacology
Head-to-head clinical analysis: LEVO T versus LEVOTHYROXINE SODIUM INTRAVENOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVO T versus LEVOTHYROXINE SODIUM INTRAVENOUS.
LEVO-T vs LEVOTHYROXINE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic form of thyroxine (T4), a thyroid hormone. It is deiodinated to triiodothyronine (T3), which binds to nuclear thyroid hormone receptors, resulting in modulation of gene transcription and increased metabolic rate.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
1.6 mcg/kg orally once daily (typical adult starting dose 50-100 mcg/day); adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days in euthyroid individuals; in hyperthyroidism, half-life shortens to 3-4 days; in hypothyroidism, it prolongs to 9-10 days. The long half-life supports once-daily dosing.
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
Renal: ~20-40% of administered levothyroxine is excreted in urine as unchanged drug and conjugates; biliary/fecal: ~40-60% is excreted in feces via bile, largely as conjugates and minor amounts of unchanged drug.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Category C
Category A/B
Thyroid Hormone
Thyroid Hormone